



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete If Known	
(use as many sheets as necessary)				Application Number	10/630,590
				Filing Date	July 29, 2003
				First Named Inventor	LU, PETER S.
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	VITA-008
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
32		US-4,777,239	10-11-88	Schoolnik et al.	
32		US-6,416,995	5-16-95	Schoolnik et al.	
32		US-5,848,459	7-15-97	Cole et al.	
32		US-5,865,535	9-9-97	Orth et al.	
32		US-5,753,233	5-19-98	Bleul et al.	
32		US-5,876,723	3-2-99	Cole et al.	
32		US-6,322,784	11-27-01	Bleul et al.	
32		US-6,344,314	2-5-02	Cole et al.	
32		US-6,391,539	5-21-02	Orth et al.	
OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
32		GARDIOL et al., ONCOGENIC HUMAN PAPILOMAVIRUS E6 PROTEINS TARGET THE DISCS LARGE TUMOUR SUPPRESSOR PROTEIN, Oncogene, (1999), 18:5487-96			
32		GLAUNSINGER et al., INTERACTIONS OF THE PDZ-PROTEIN MAGI-1 WITH ADENOVIRUS E4-ORF1 AND HIGH-RISK PAPILOMAVIRUS E6 ONCOPROTEINS, Oncogene, (2000), 19:5270-80			
32		KIYONO et al., BINDING OF HIGH-RISK HUMAN PAPILOMAVIRUS E6 ONCOPROTEINS TO THE HUMAN HOMOLOGUE OF THE DROSOPHILA DISCS LARGE TUMOR SUPPRESSOR PROTEIN, Proc. Natl. Acad. Sci., (1997), 94:11612-6			
32		LEE et al., BINDING OF HUMAN VIRUS ONCOPROTEINS TO HDLG/SAP97, A MAMMALIAN HOMOLOG OF THE DROSOPHILA DISCS LARGE TUMOR SUPPRESSOR PROTEIN, Proc. Natl. Acad. Sci., (1997), 94:6670-5			
32		MESCHDE et al., ANTIBODIES AGAINST EARLY PROTEINS OF HUMAN PAPILOMAVIRUSES AS DIAGNOSTIC MARKERS FOR INVASIVE CERVICAL CANCER, J. Clin. Microbiol., (1998), 36:475-80			
32		MUNGER et al., THE ROLE OF HUMAN PAPILOMAVIRUSES IN HUMAN CANCERS, Front. Biosci., (2002), 7:d641-9			
32		PIM et al., HPV-18 E6 ¹ PROTEIN MODULATES THE E6-DIRECTED DEGRADATION OF P53 BY BINDING TO FULL-LENGTH HPV-18 E6, Oncogene, (1999), 18:7403-8			
Examiner Signature	Date Considered			11/25/05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.